Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has assisted PulPac in connection with it obtaining a €20 million financing from the European Investment Bank
Mandate

Vinge has assisted PulPac in connection with it obtaining a €20 million financing from the European Investment Bank

July 18, 2025 Banking and Finance

Vinge has assisted Gothenburg-based sustainable packaging technology company PulPac in connection with it obtaining a €20 million (around 220 million Swedish kronor) financing from the European Investment Bank (EIB).

The financing is structured as a venture debt loan – a form of growth financing tailored to innovative companies. It is provided under the InvestEU programme, which supports the EU’s green transition and efforts to spur innovation, industrial resilience and sustainable economic growth. The EIB financing will support development and commercialization of a fiber-based technology developed by PulPac as an alternative to single-use plastics.

The Vinge team consisted of Kristian Ford (responsible partner), Henrik Ossborn and Agaton Lindgren (banking and finance).

Read more in the press release from PulPac

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025